London, UK – 30 August 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today notes that the US Food and Drug Administration (FDA) has approved Novartis’ CAR-T cell therapy CTL019 (tisagenlecleucel, brand name KymriahTM) for the treatment of relapsed and… Read More
The agreement is to explore a next generation gene and cell therapy manufacturing… Read More
London, UK – 07 August 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today announces that it has been granted a Manufacturer/Importer License (MIA), from the UK Medicines and Healthcare products Regulatory Agency (“MHRA”), to manufacture and distribute lentiviral vector… Read More
London, UK – 13 July 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today notes that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee voted unanimously 10 to 0 in favour of approval of Novartis investigational therapy… Read More
Oxford, UK – 6 July 2017: Oxford BioMedica plc (LSE:Oxford Biomedica) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has signed an agreement with Novartis for the commercial and clinical supply of lentiviral vectors used to generate CTL019 (tisagenlecleucel) and other undisclosed… Read More
London, UK – 30 June 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, is pleased to announce it has today completed a new $55 million debt facility with Oaktree Capital Management – Strategic Credit Strategy (“Oaktree”). The facility has… Read More
Oxford, UK – 14 June 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today notes the findings reported by Novartis on its global multi-centre Phase II JULIET study evaluating the efficacy and safety of CTL019 (tisagenlecleucel-T), an investigational chimeric antigen… Read More
London, UK – 7 June 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, notes that the US Food and Drug Administration (FDA) has scheduled an Oncologic Drugs Advisory Committee meeting on 12 July 2017 to review the CTL019 (tisagenlecleucel-T) Biologics… Read More
Oxford, UK – 06 June 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today announces that John Dawson, Chief Executive Officer, will be presenting at the Jefferies 2017 Healthcare Conference in New York on 06 June 2017 at 1300 BST… Read More
Oxford, UK – 30 March 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, is pleased to note the announcement by Novartis that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) filing and granted priority… Read More
~ Data demonstrates benefits of the Group’s proprietary “TRiP” system in enhancing production yields for a broad range of gene therapy vectors Oxford, UK – 27 March 2017: Oxford BioMedica plc (LSE:Oxford Biomedica) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces the… Read More